Status:
RECRUITING
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Lead Sponsor:
Verve Therapeutics, Inc.
Conditions:
Heterozygous Familial Hypercholesterolemia
Premature Coronary Heart Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature...
Eligibility Criteria
Inclusion
- Diagnosis of HeFH or premature CAD
Exclusion
- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
Key Trial Info
Start Date :
April 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT06164730
Start Date
April 30 2024
End Date
August 1 2027
Last Update
December 17 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Study Center
Dothan, Alabama, United States, 36305
2
Clinical Study Center
Adelaide, Australia
3
Clinical Study Center
Melbourne, Australia
4
Clinical Study Center
Sydney, Australia